CLINICAL_TRIALS
ClinicalTrials.gov record update
Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02295722
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:23.778856+00:00
- Published At
- 2024-07-08T00:00:00+00:00
- Record Updated At
- 2024-07-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Hodgkin\u0027s Lymphoma - Relapsed/Refractory", "Non-Hodgkin\u0027s Lymphoma - Aggressive", "Follicular Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-07-08"- protocolSection.identificationModule.nctId
"NCT02295722"- protocolSection.identificationModule.officialTitle
"Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.